Welcome to our dedicated page for Stoke Therapeutics SEC filings (Ticker: STOK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Stoke Therapeutics filings document regulatory disclosures for a Nasdaq-listed biotechnology company developing RNA medicines, including zorevunersen for Dravet syndrome. Recent 8-K reports cover quarterly financial results, clinical-program updates, capital resources, material agreements, lease obligations, board appointments, executive compensation, auditor changes, and Regulation FD disclosures.
The company’s definitive proxy materials describe annual meeting voting matters, director elections, board committee structure, governance practices, equity compensation, and related stockholder information. Filings also identify its common stock registered on the Nasdaq Global Select Market under STOK.
Stoke Therapeutics will hold its 2026 Annual Meeting of Stockholders virtually on June 3, 2026 at 9:00 a.m. Eastern. Stockholders of record as of April 7, 2026, when 62,271,082 common shares were outstanding, may vote online or by proxy.
Investors are asked to elect three Class I directors, ratify Ernst & Young LLP as the new independent registered public accounting firm for 2026, and approve on an advisory basis the compensation of named executive officers. The company highlights its board independence, committee structure, clawback and insider trading policies, human capital metrics, and a mix of salary, cash bonuses, options and RSUs for executives, including leadership transition arrangements for the former and current CEO.
Stoke Therapeutics director Clare Kahn received a new stock option award covering 30,782 shares of Common Stock. The option has an exercise price of $32.79 per share and expires in 2036. It vests in 12 equal quarterly installments starting July 1, 2026, contingent on continued service.
Stoke Therapeutics director Kahn Clare has filed an initial Form 3 insider ownership report. This filing establishes Clare’s status as a director and baseline reporting position under insider disclosure rules. The filing does not show any insider share purchases, sales, or other transactions at this time.
Stoke Therapeutics expanded its Board of Directors to ten members and appointed Clare Kahn, Ph.D. as a Class I director, effective April 3, 2026, with a term running until the 2026 annual meeting. She will serve on the Nominating and Corporate Governance Committee and chair the Research and Development Committee. Dr. Kahn is deemed an independent director and signed the company’s standard indemnity agreement.
Under the non-employee director compensation program, she will receive a $45,000 annual cash retainer and an initial stock option for 30,782 shares, with an approximate grant-date fair value of $724,000, vesting in twelve equal quarterly installments. The accompanying press release highlights Stoke’s lead RNA medicine candidate, zorevunersen, now in Phase 3 development for Dravet syndrome and partnered globally with Biogen outside North America.
Stoke Therapeutics, Inc.’s Chief Medical Officer, Barry Ticho, executed an open-market sale of 1,838 shares of Common Stock. The shares were sold at an average price of $32.66 per share. After this transaction, he continues to hold 38,864 shares directly.
The sale occurred under a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person, indicating the transaction was scheduled in advance rather than timed discretionarily.
Insider proposed sales under Rule 144. The excerpt lists 10b5-1 sales by Baruch S. Ticho of Common stock for 1,461 shares on 03/19/2026 ($43,815.39), 6,686 shares on 03/18/2026 ($209,568.72), and 6,164 shares on 03/17/2026 ($203,450.99). It also shows 1838 Restricted Stock Units dated 12/01/2025.
Stoke Therapeutics changed its independent auditor, dismissing KPMG LLP and appointing Ernst & Young LLP (EY) as its new independent registered public accounting firm for the fiscal year ending December 31, 2026.
The company states that KPMG’s audit reports for 2024 and 2025 contained no adverse or qualified opinions, and there were no disagreements or reportable events under SEC rules through March 23, 2026. KPMG provided a letter to the SEC agreeing with these disclosures, which is included as an exhibit.
The Vanguard Group filed an amendment to its Schedule 13G on behalf of its reporting entity to state it holds 0 shares of Stoke Therapeutics Inc. common stock following an internal realignment effective January 12, 2026 that disaggregated certain subsidiaries' holdings under SEC Release No. 34-39538. The amendment is signed by a Vanguard officer on March 27, 2026.
Stoke Therapeutics general counsel Jonathan Allan sold 9,293 shares of common stock in open-market transactions. The sales occurred on March 20, 2026 at weighted average prices of $33.64 and $34.41 per share under a pre-arranged Rule 10b5-1 trading plan. He continues to hold 19,543 shares directly after these trades.
STOK filed a Form 144 notice reporting an affiliate sale plan. The filing lists 9,293 restricted stock units to be sold and shows two reported sales by Jonathan Allan on 03/17/2026 (4,267 shares) and 03/18/2026 (4,628 shares) with cash amounts shown.